Live Breaking News & Updates on Infinatamab Deruxtecan

Stay updated with breaking news from Infinatamab deruxtecan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer. ....

Terufumi Kato , Kanagawa Cancer Center , Department Of Thoracic Oncology , Chief Physician , Thoracic Oncology , Infinatamab Deruxtecan , I Dxd Ds 7300 , 2023 Iaslc World Conference On Lung Cancer , Dato Dxd , Non Small Cell Lung Cancer ,

Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC

Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer. ....

Melissal Johnson , Oncology Department , Lung Cancer Research , Sarah Cannon Research Institute , Tristar Centennial Medical Center , Medical Executive Committee , Patients With Small Cell Lung Cancer , Infinatamab Deruxtecan , I Dxd Ds 7300 , 2023 Iaslc World Conference On Lung Cancer ,